

17 April 2026

To the Independent Shareholders

Dear Sirs,

**MANDATORY UNCONDITIONAL CASH OFFER BY
ARISTO SECURITIES LIMITED FOR AND ON BEHALF OF
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
TO ACQUIRE ALL THE ISSUED SHARES OF
GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD.
(OTHER THAN THOSE ALREADY
OWNED AND/OR AGREED TO BE ACQUIRED
BY FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED,
ITS ULTIMATE BENEFICIAL OWNERS AND
PARTIES ACTING IN CONCERT WITH ANY OF THEM)**

INTRODUCTION

We refer to the Composite Document jointly issued by the Company and the Offeror dated 17 April 2026, of which this letter forms part. Unless the context otherwise requires, terms used in this letter have the same meanings as those defined in the Composite Document.

We have been appointed by the Company to form the Independent Board Committee to consider the Offer and to advise the Independent Shareholders as to, in our opinion, whether or not the Offer is fair and reasonable and to make recommendation in respect of acceptance of the Offer.

SBI China Capital Hong Kong Securities Limited has been appointed as the Independent Financial Adviser with our approval to make recommendation to us in respect of the Offer and, in particular, whether the Offer is fair and reasonable and to make recommendation in respect of the acceptance of the Offer. Details of its advice and recommendation, together with the principal factors and reasons which it has considered before arriving at such recommendation, are set out in the “Letter from the Independent Financial Adviser” in the Composite Document.

We also wish to draw your attention to the “Letter from the Board” and the additional information set out in the Appendices to the Composite Document.

Taking into account the terms of the Offer and the independent advice and recommendations from the Independent Financial Adviser, we consider that the Offer is not fair and reasonable so far as the Independent Shareholders are concerned. Accordingly, we advise the Independent Shareholders not to accept the Offer.

Notwithstanding our recommendations, the Independent Shareholders are strongly advised that the decision to realise or to hold their investment is subject to individual circumstances and investment objectives. If in doubt, the Independent Shareholders should consult their own professional advisers for professional advice.


The Independent Shareholders are recommended to read the full text of the section headed “Letter from the Independent Financial Adviser” set out in the Composite Document.

Yours faithfully,
For and on behalf of
the Independent Board Committee
Guanze Medical Information Industry (Holding) Co., Ltd.

Dr. Zhao Bin
Independent
non-executive Director




Dr. Chang Shiwang
Independent
non-executive Director



Chang Shiwang

Dr. Wong Man Hin Raymond
Independent
non-executive Director

DocuSigned by:

E537FCA35C9C4A9...